iRadimed (FRA:46K) ROCE % : 27.11% (As of Dec. 2024)

View and export this data going back to 2019. Start your Free Trial

What is iRadimed ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. iRadimed's annualized ROCE % for the quarter that ended in Dec. 2024 was 27.11%.

iRadimed ROCE % Historical Data

The historical data trend for iRadimed's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

iRadimed ROCE % Chart

iRadimed Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

ROCE %

Get a 7-Day Free Trial

-1.14

14.28

21.08

25.84

27.01

iRadimed Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
ROCE %	Get a 7-Day Free Trial															26.28	24.35	27.77	27.05	27.11

iRadimed ROCE % Calculation

iRadimed's annualized ROCE % for the fiscal year that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	20.977	/	( ( (84.507 - 14.972)	+	(93.901 - 8.129) )	/ 2 )
	=	20.977	/	( (69.535	+	85.772)	/ 2 )
	=	20.977	/	77.6535
	=	27.01 %

iRadimed's ROCE % of for the quarter that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	22.156	/	( ( (84.917 - 7.265)	+	(93.901 - 8.129) )	/ 2 )
	=	22.156	/	( ( 77.652	+	85.772 )	/ 2 )
	=	22.156	/	81.712
	=	27.11 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

iRadimed (FRA:46K) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

iRadimed ROCE % Related Terms

Thank you for viewing the detailed overview of iRadimed's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

iRadimed Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » iRadimed Corp (FRA:46K) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

IRMD:USA

Address

1025 Willa Springs Drive, Winter Springs, FL, USA, 32708

Website

https://www.iradimed.com

iRadimed Corp develops, manufactures, markets and distributes a Magnetic Resonance Imaging (MRI) compatible intravenous (IV) infusion pump system, and MRI compatible patient vital signs monitoring system, and accessories and services relating to them. The company provides a non-magnetic IV infusion pump system which is designed to be safe for use during MRI procedures. The MRI products of the company are sold to hospitals and acute care facilities in the United States and internationally. It generates majority revenue from United States.

iRadimed Headlines

No Headlines